Cabaletta Bio

About Cabaletta Bio

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing and launching potentially breakthrough engineered T cell therapies for patients with autoimmune diseases. Their mission is to transform the treatment of autoimmune diseases by utilizing their innovative CABA® platform to deliver deep, durable, and potentially curative responses.

Products & Services

CABA-201:An investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain, currently under development for systemic lupus erythematosus (SLE), myositis, systemic sclerosis, generalized myasthenia gravis, and other autoimmune diseases with high unmet need. It is designed as a one-time infusion to potentially eliminate B cells and enable an immune system reset.

CABA® Platform:A proprietary platform used to develop T cell therapies aimed at providing deep and durable responses for autoimmune diseases through B cell ablation.

Specialties

Engineered T Cell Therapies Autoimmune Disease Treatment Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) CD19-CAR T Cell Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2025-06-11 FD: 2025-06-11	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2023-05-22 FD: 2023-05-22	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 87000000 MR: - FA: $87 million FAN: 87000000	D: 2023-05-17 FD: 2023-05-17	4 investors

Public Offering Latest

2025-06-11

$100.0M

3 investors (Pro only)

Public Offering 2023-05-22

$100.0M

Public Offering 2023-05-17

$87.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Aimee Payne

Irving Professor and Chair of Dermatology at Columbia University

M

Michael C. Milone

Associate Professor of Pathology and Laboratory Medicine

D

Drew Weissman

Professor of Medicine

J

Jay Siegel

Chair of the National Academies' Forum on Regenerative Medicine

C

Carl June

Richard W. Vague Professor in Immunotherapy

I

Iain McInnes

Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Cabaletta Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised